Faron Pharmaceuticals Oy - Finland-based biopharmaceutical company with a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy - Says updated results from the phase 1, 2, Matins study of its cancer immunotherapy drug candidate Bexmarilimab, strengthened its belief that it "can increase survival in patients with a variety of late-stage solid tumours."
Says updated results from the Matins study include patients from part one and part two of the trial. Current estimate for median progression free survival for all these patients was 59 days. Estimated median overall survival for all patients was 151 days.
Chief Executive Officer Markku Jalkanen says: "We look forward to discussing these results with the FDA and finalizing plans for the Part III expansion cohorts, which we hope to convert to pivotal stage development for a regulatory submission. Additionally, all biomarker data are currently being analyzed for potential patient selection purposes and we simultaneously continue to advance our plans to investigate bexmarilimab in additional clinical settings, including neoadjuvant therapy, in combination with checkpoint inhibitors and as a treatment for hematological malignancies."
Current stock price: 450.00 pence, up 9.1% on Friday
Year-to-date change: up 73%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)